Picture of Daewon Pharmaceutical Co logo

003220 Daewon Pharmaceutical Co Cashflow Statement

0.000.00%
kr flag iconLast trade - 00:00
HealthcareBalancedSmall CapNeutral

Annual cashflow statement for Daewon Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

2021
December 31st
R2022
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:Annual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line6,61130,65723,4639,045-4,013
Depreciation
Amortisation
Non-Cash Items23,70324,93720,53232,71216,798
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-23,813-48,549-9,822-31,8175,781
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities24,30726,41351,73430,03542,313
Capital Expenditures-11,707-13,365-20,611-53,582-42,131
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items-29,908-7,410-47,65610,60730,714
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities-41,615-20,775-68,267-42,975-11,417
Financing Cash Flow Items-1,906-3,241-4,434-6,555-7,632
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities48,527-20,41119,513-298-929
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash31,258-14,7273,013-12,92630,140